Help your patients
 with Alagille syndrome
 rise above cholestatic pruritus so they can


Used by

LIVMARLI is FDA approved for the treatment of cholestatic pruritus in patients with Alagille syndrome who are ≥3 months of age.2

Help Patients  RISE ABOVE  Cholestatic Pruritus
Hourglass icon

First and Only Treatment to Provide Early Improvements in Cholestatic Pruritus With Long-Term Impact3-5

See the Data
Shield icon

>6 Years of Clinical Data Plus Real-World Use1,2,6

View Safety
Conversation bubble icon

Exceptional Access and Patient Support

Learn About Mirum Access Plus
Real patient and caregiver stories

Hear from patients and families—and learn about the difference LIVMARLI has made in their lives.

Watch the Videos
patients have used LIVMARLI to battle bile acid buildup.1,2,6*
*Number includes all patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI in clinical studies, as well as those treated in the United States commercially and through the expanded access program.


New information is always sprouting up

Stay in the Know

To receive more information about LIVMARLI as it becomes available, please fill out the form below.


By completing this form, you agree to our Terms of Use and Privacy Policy.


Your sign-up was successful!

Be on the lookout for a welcome email from Mirum soon. Make sure to add to your address book so that our emails go directly to your inbox.

We're having some connection trouble.

Refresh the page and try submitting your form again. Note: This issue may occur if your email is already registered. Please check your inbox and spam folder to make sure you're receiving information. If the issue persists, please contact us.

Collapse icon

Important Safety Information


LIVMARLI is contraindicated in patients with prior or active hepatic decompensation events (eg, variceal hemorrhage, ascites, or hepatic encephalopathy).

Warnings and Precautions

Hepatotoxicity: LIVMARLI treatment is associated with a potential for drug-induced liver injury. In the Alagille syndrome trial, treatment-emergent elevations of liver tests or worsening of liver tests occurred.

Obtain baseline liver tests and monitor during treatment. Liver-related adverse reactions and physical signs of hepatic decompensation should also be monitored. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Permanently discontinue LIVMARLI if a patient experiences the following: persistent or recurrent liver test abnormalities, clinical hepatitis upon rechallenge, or a hepatic decompensation event.

Gastrointestinal (GI) Adverse Reactions: Diarrhea and abdominal pain were reported as the most common adverse reactions. Monitor for dehydration and treat promptly. Consider reducing the dosage or interrupting dosing if a patient experiences persistent diarrhea or has diarrhea with bloody stool, vomiting, dehydration requiring treatment, or fever.

Fat-Soluble Vitamin Deficiency: Patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may adversely affect absorption of FSV. If bone fractures or bleeding occur, consider interrupting LIVMARLI and supplement with FSVs. LIVMARLI can be restarted once FSV deficiency is corrected and maintained at corrected levels.

Adverse Reactions

The most common adverse reactions are diarrhea, abdominal pain, vomiting, FSV deficiency, liver test abnormalities, and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI. A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Dosing Information

LIVMARLI should be taken 30 minutes before a meal. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.